Table 6.
Treatment responses among different inhalation therapies in CAT≥10 group*
| Total | LAMA | LABA + LAMA | LABA + ICS | LABA + LAMA + ICS | P-value | |
|---|---|---|---|---|---|---|
|
Total number of participants
|
2664 |
575 (21.6) |
292 (11.0) |
305 (11.4) |
1492 (56.0) |
|
|
Exacerbations, MD (IQR)
|
0 (0–1) |
0 (0–2) |
0 (0–1) |
0 (0–2) |
0 (0–1) |
<0.001 |
|
Exacerbations
|
|
|
|
|
|
<0.001 |
| Yes |
1017 (39.2) |
257 (45.7) |
96 (34) |
125 (41.8) |
539 (37.1) |
|
| No |
1580 (60.8) |
305 (54.3) |
186 (66) |
174 (58.2) |
915 (62.9) |
|
|
Frequent exacerbations
|
|
|
|
|
|
<0.001 |
| Yes |
534 (20.6) |
149 (26.5) |
43 (15.2) |
68 (22.7) |
274 (18.8) |
|
| No |
2063 (79.4) |
413 (73.5) |
239 (84.8) |
231 (77.3) |
1180 (81.2) |
|
|
Hospitalisations, MD (IQR)
|
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0 (0–0) |
0.256 |
|
Hospitalisations
|
|
|
|
|
|
0.296 |
| Yes |
611 (23.5) |
126 (22.4) |
60 (21.3) |
63 (21.1) |
362 (24.9) |
|
| No |
1986 (76.5) |
436 (77.6) |
222 (78.7) |
236 (78.9) |
1092 (75.1) |
|
|
All-cause mortality
|
|
|
|
|
|
0.678 |
| Yes |
67 (2.5) |
13 (2.3) |
10 (3.4) |
6 (2) |
38 (2.5) |
|
| No |
2597 (97.5) |
562 (97.7) |
282 (96.6) |
299 (98) |
1454 (97.5) |
|
|
Prescription outcomes
|
|
|
|
|
|
0.002 |
| Adjust treatment |
591 (22.2) |
158 (27.5) |
50 (17.1) |
62 (20.3) |
321 (21.5) |
|
| Continuous using | 2073 (77.8) | 417 (72.5) | 242 (82.9) | 243 (79.7) | 1171 (78.5) |
CAT – COPD assessment test, COPD – chronic obstructive pulmonary disease, ICS – inhaled corticosteroid, IQR – interquartile range, LABA – long-acting β2-agonist, LAMA – long-acting muscarinic antagonist, MD – median
*Presented as n (%) unless specified otherwise.